Amicus Therapeutics Announces Additional Preliminary Results From Ongoing Phase 2 Chaperone-Enzyme Replacement Therapy (ERT) Study for Fabry Disease

[at noodls] – Amicus Therapeutics Announces Additional Preliminary Results From Ongoing Phase 2 Chaperone-Enzyme Replacement Therapy (ERT) Study for Fabry Disease Drug-Drug Interaction Study Evaluating Pharmacokinetics … more

View todays social media effects on FOLD

View the latest stocks trending across Twitter. Click to view dashboard